Characteristics of patients at time of diagnosis of BKPyV-HC. (A) Laboratory data, comorbidities, and medication use. (B) Presence of copathogens detected at time of diagnosis. (C) Specific clinical outcomes observed during their course. ^aCell counts are from the closest test within 14 days before or after beginning of BKPyV-HC and are measured in cells/µL. ^bIncluding diagnoses up to 90 days before or 7 days after beginning of BKPyV-HC. Grade is the peak grade of the episode. ^cIncludes cidofovir use up to 7 days before or after baseline date. Among the 19 patients on cidofovir, 4 (21%) had a concomitant diagnosis of adenovirus. ^dBedi score 2 indicates macroscopic hematuria, and 3 indicates presence of clots.32 ^ePain medication use includes opiates (n = 74), oxybutynin (n = 46), or phenazopyridine (n = 72). ^fTransfusion includes red blood cell (n = 92) or platelet (n = 79) transfusions. ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count.